The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be ...

Worth up to $850 million, the partnership provides “further validation” for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.

In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change ...

Backed with $82 million and led by two of BioMarin’s former executives, Mendra plans to acquire rare disease assets and use ...

While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed ...

Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, ...

Amid patent expirations, litigation and tariff costs, J&J says it expects more growth ahead, fueled in part by its blood ...

The decision comes months after the FDA had suspended the vaccine’s license. One analyst speculated the company might shelve the product altogether.

The deal is the first for new CEO Luke Miels as the British drugmaker looks to overcome pressure on its HIV and vaccines ...

In an interview with BioPharma Dive, the veteran biotech CEO said there remains a “significant opportunity” for young ...

Clinical trial delays impact outcomes. Learn why CROs need a supply chain partner they can trust to reduce delays and help ...

More than 3,000 prescriptions were written for Novo’s GLP-1 pill in its first week on the market. Elsewhere, Emergent reached ...